3.5.7. classical angiomyolipoma. classical angiomyolipoma (aml)/pecoma kidney benign mesenchymal tumour, occur sporadically part tuberous sclerosis complex . overall prevalence 0.44%, 0.6% female 0.3% male populations. 5% patients present multiple amls . angiomyolipoma belongs family so-called pecomas (perivascular epithelioid cell tumours), characterised proliferation perivascular epithelioid cells. pecomas behave aggressively even metastasise, classic amls completely benign . ultrasound, ct, mri often lead diagnosis amls due presence adipose tissue; however, fat-poor aml, diagnostic imaging cannot reliably identify lesions. percutaneous biopsy rarely useful. renal tumours cannot clearly identified benign initial diagnostic work-up treated according recommendations provided treatment rcc. tuberous sclerosis, aml found enlarged lymph nodes (lns), represent metastatic spread multicentric spread amls. rare cases, extension non-malignant thrombus renal vein inferior vena cava (ivc) found, associated angiotrophic-type growth aml. epithelioid aml, rare variant aml, consists least 80% epithelioid cells mean age onset 50 years (range 30-80 years), without gender predilection . epithelioid amls potentially malignant variable proportion cases aggressive behaviour . criteria predict biological behaviour epithelioid aml proposed 2022 . angiomyolipoma, general, slow consistent growth rate, minimal morbidity . subtypes aml oncocytic aml aml epithelial cysts . cases, larger amls cause local pain. main complication amls spontaneous bleeding retroperitoneum collecting system, life threatening. bleeding caused spontaneous rupture tumour. little known risk factors bleeding, believed increase tumour size may related angiogenic component tumour includes irregular blood vessels . major risk factors bleeding tumour size, grade angiogenic component, presence tuberous sclerosis. 3.5.7.1. treatment angiomyolipoma active surveillance appropriate option amls (48%). group patients as, 11% amls showed growth, spontaneous bleeding reported 2%, resulting active treatment 5% patients (le: 3). association aml size risk bleeding remains unclear traditionally used 4-cm cut-off per se trigger active treatment . surgery indicated, nss preferred option, technically feasible. main disadvantages less invasive selective arterial embolisation (sae) recurrences need secondary treatment (0.85% surgery vs. 31% sae). thermal ablation limited data available, option used less frequently . active treatment (sae, surgery ablation) instigated case persistent pain, ruptured aml (acute repeated bleeding) case large aml. specific patient circumstances may influence choice offer active treatment, patients high risk abdominal trauma, females childbearing age patients follow-up access emergency care may inadequate. selective arterial embolisation option case life-threatening aml bleeding. patients diagnosed tuberous sclerosis, size reduction often bilateral amls induced inhibiting mtor pathway using everolimus, demonstrated rcts . small phase ii trial(n = 20), efficacy everolimus demonstrated sporadic aml well. 25% greater reduction tumour volume four six months demonstrated 55.6% 71.4% patients, respectively. however, 20% patients withdrawn due toxicities 40% self-withdrew study due side effects . table 3.2: renal cortical tumours recommendations treatment (strength rating: weak) entityclinical relevant notesmalignant potentialtreatmentcollecting duct carcinomaformerly bellini duct carcinoma. hemoglobinopathy smarcb1 abnormality. rare, often presenting advanced stage (n+ 44% m1, 33% diagnosis). hr css comparison ccrcc 4.49 .high, aggressive. median survival 30 months .surgery. systemic therapy surgery metastatic disease .clear-cell papillary renal cell tumourpatient ackd, 100 times greater risk compared general population .indolentsurgery, nss, discuss active surveilance.mucinous tubular spindle cell carcinomatumour associated loop henle. < 1% renal neoplasm. female predilection (3–4:1) .intermediatesurgery, nss.tubulocystic rccrare (< 1%). mainly men, imaging bosniak iii iv.low (90% indolent)surgery, nss.eosinophilic solid cystic rcc (esc rcc)usually alteration tcs genes. predominantly adult women. tsc (tuberous sclerosis complex) syndrome.rarely metastatic.nss.tfe3 re-arranged rccgene fusions involving tfe3 one many different partner genes. formerly translocation rcc (trcc) xp11.2. appr. 40 % paediatric rcc 1.6–4% adult rcc .survival similar clear cell rccsurgery. systemic therapy metastatic disease.tfeb altered (re-arranged amplified) rccgene fusions involving tfeb transcription factor, typically via t(6;11)(p21;q12) translocation resulting malat1-tfeb gene fusion. formerly translocation rcc t(6;11). less common tfe3-re-arranged rcc. appr. 100 cases literature . tfeb-amplified older patient worse prognosis.more indolent tfe3-rearranged rcc, fewer 10% cases resulting patient death.surgery. systemic therapy metastatic.eloc (formerly tcbe1)-mutated rcctwenty cases described literature. typically t1.indolent. 2 metastatic cases described.nss.fumarate hydratase-deficient rccformerly hereditary leiomyomatosis rcc-associated rcc. alterations fh gene. autosomal dominant. 21–30% lifetime risk rcc . cutanous leiomyomas, female uterine leiomyoma leiomyosarcoma. common males. median age 44 years .often aggressive.immediate surgery. data treatment metastatic disease. genetic counselling family. imaging screening relatives .succinate dehydrogenase-deficient rcc(sdh-deficient rcc)rare. 0.05–0.2 % rccs.a metastatic rate 11%surgery, nss. long-term follow-up surveillance sdh-deficient neoplasms (i.e. paraganglioma, sdh-deficient gastrointestinal stromal tumour, pituitary adenoma) indicated cases associated germline mutation .alk-rearranged rccgene fusions involving anaplastic lymphoma kinase gene (alk) chromosome 2p23. appr. 40 cases described.low (90% indolent)surgery, nss.metanephric tumoursdivided metanephric adenoma, adenofibroma, metanephric stromal tumours.benignnss.mixed epithelial stromal renal tumourit encompasses 2 benign leasions - mixed epithelial stromal tumour kidney (mest) adult cystic nephroma. imaging – bosniak type iii iif/iv. overwhelmingly women (7:1).benignactive surveillance. nss.renal cysts/cystic lesionssimple cysts frequently occurring, occurring septa, calcifications solid components require follow-up and/or management.mostly benigntreatment follow-up recommendation based bosniak classification.